14.29 USD
-0.56 (-3.77%)
At close: Jan 30, 2026
14.2997 USD
+0.01 (+0.07%)
After Hours: 1/30/2026, 8:00:00 PM
Overall AMLX gets a fundamental rating of 4 out of 10. We evaluated AMLX against 190 industry peers in the Pharmaceuticals industry. AMLX has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, AMLX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- AMLX had negative earnings in the past year.
- AMLX had a negative operating cash flow in the past year.
- In the past 5 years AMLX reported 4 times negative net income.
- AMLX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -41.15%, AMLX is in line with its industry, outperforming 43.16% of the companies in the same industry.
- AMLX has a Return On Equity (-44.96%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.15% | ||
| ROE | -44.96% | ||
| ROIC | N/A |
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AMLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, AMLX has more shares outstanding
- AMLX has more shares outstanding than it did 5 years ago.
- AMLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 28.71 indicates that AMLX is not in any danger for bankruptcy at the moment.
- AMLX's Altman-Z score of 28.71 is amongst the best of the industry. AMLX outperforms 90.00% of its industry peers.
- There is no outstanding debt for AMLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 28.71 |
ROIC/WACCN/A
WACC9.42%
2.3 Liquidity
- A Current Ratio of 13.70 indicates that AMLX has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 13.70, AMLX belongs to the best of the industry, outperforming 82.63% of the companies in the same industry.
- AMLX has a Quick Ratio of 13.70. This indicates that AMLX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 13.70, AMLX belongs to the best of the industry, outperforming 83.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.7 | ||
| Quick Ratio | 13.7 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.70% over the past year.
- AMLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
- AMLX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 127.75% yearly.
EPS 1Y (TTM)2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.42%
Revenue 1Y (TTM)-100%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%-100%
3.2 Future
- The Earnings Per Share is expected to grow by 17.45% on average over the next years. This is quite good.
- AMLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.01% yearly.
EPS Next Y36.76%
EPS Next 2Y21.14%
EPS Next 3Y12.91%
EPS Next 5Y17.45%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-20.17%
Revenue Next 5Y25.01%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- AMLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year AMLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AMLX's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.14%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
- AMLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What is the fundamental rating for AMLX stock?
ChartMill assigns a fundamental rating of 4 / 10 to AMLX.
What is the valuation status of AMYLYX PHARMACEUTICALS INC (AMLX) stock?
ChartMill assigns a valuation rating of 0 / 10 to AMYLYX PHARMACEUTICALS INC (AMLX). This can be considered as Overvalued.
Can you provide the profitability details for AMYLYX PHARMACEUTICALS INC?
AMYLYX PHARMACEUTICALS INC (AMLX) has a profitability rating of 1 / 10.
What is the financial health of AMYLYX PHARMACEUTICALS INC (AMLX) stock?
The financial health rating of AMYLYX PHARMACEUTICALS INC (AMLX) is 8 / 10.